Board of Directors

David Stack

Pacira Pharmaceuticals

Dave Stack is currently the Chief Executive Officer and Chairman of Pacira Pharmaceuticals, Inc. He is also a Managing Director at MPM Capital.

From September 2001 until August 2004, Mr. Stack was President,

Dave Stack is currently the Chief Executive Officer and Chairman of Pacira Pharmaceuticals, Inc. He is also a Managing Director at MPM Capital.

From September 2001 until August 2004, Mr. Stack was President, CEO and Director of The Medicines Company (NASDAQ: MDCO). Prior to The Medicines Company, he was the CEO of Stack Pharmaceuticals, Inc., where The Medicines Company was one of its primary customers. From May 1995 to December 1999, he served as the President and General Manager of Innovex, Inc., responsible for the Americas. Innovex, Inc. was a commercial solutions company offering a full range of marketing, sales and clinical development capabilities to pharmaceutical and biotechnology customers, and was sold to Quintiles in November 1997 for $897 million. From April 1993 to May 1995, he was the Vice President of Business Development and Marketing for Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company focusing on monoclonal antibodies in infectious disease and oncology. From May 1992 to March 1993, Mr. Stack was the Director of Business Development and Planning for Infectious Disease, Oncology and Virology for Roche Labs where he was the Therapeutic World Leader for Infectious Disease. Prior to that role, he held various positions with Roche Labs for approximately 12 years and was a retail and hospital pharmacist for three years after graduating from Albany College of Pharmacy. He also holds a Bachelor of Science in Biology from Siena College, where he is currently a Trustee.

Mr. Stack was recognized as the Ernst and Young Entrepreneur of the Year in 2003 (New Jersey Healthcare). He is a Director of Amarin Corporation plc and Medivo Inc, serves as Chairman of Chiasma, Inc. and is on the Board of Directors of the Biotechnology Industry Organization’s (BIO) Emerging Company and Health Sections.

Paul Hastings

OncoMed Pharmaceuticals

Paul Hastings has served as President, Chief Executive Officer and a member of the Board of Directors of OncoMed Pharmaceuticals since January 2006. In August of 2013, he was elected Chairman of the Board

Paul Hastings has served as President, Chief Executive Officer and a member of the Board of Directors of OncoMed Pharmaceuticals since January 2006. In August of 2013, he was elected Chairman of the Board

Prior to joining OncoMed, Mr. Hastings was President and Chief Executive Officer of QLT,Inc. Before this role, he served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. Prior to Axys, he was President of Chiron Biopharmaceuticals, and also held a variety of management positions of increasing responsibility at Genzyme Corporation, including President of Genzyme Therapeutics Europe and President of Worldwide Therapeutics.

Mr. Hastings currently serves on the Board of Directors at Relypsa Inc., a clinical-stage biopharmaceutical company, and the Bay Area Biosciences Association (Bay Bio). He also serves on the Board of Directors and as Executive Committee Chair of the Emerging Companies Section of the Biotechnology Industry Organization (BIO). In June 2013, Mr. Hastings was elected Lead Director of the Board of Directors at Pacira Pharmaceuticals, where he had been a Board member since June 2011.

He received a Bachelor of Science degree in pharmacy from the University of Rhode Island.

Laura Brege

Former CEO of Nodality, Inc.

Laura Brege currently serves as a consultant to life sciences companies. From 2012 to 2015, she served as the President and Chief Executive Officer of Nodality, Inc. Prior to this position, she served as Executive

Laura Brege currently serves as a consultant to life sciences companies. From 2012 to 2015, she served as the President and Chief Executive Officer of Nodality, Inc. Prior to this position, she served as Executive Vice President, Corporate Affairs, for Onyx Pharmaceuticals. In this role, Ms. Brege was responsible for the oversight of all external relationships, including medical and scientific affairs, government affairs and public affairs.

Previously, Ms. Brege held the roles of Chief Operating Officer, Executive Vice President and Chief Business Officer for Onyx. In these roles, she oversaw the expansion of key corporate capabilities and strengthened the company’s financial position by significantly adding to its cash reserves. Prior to joining Onyx in 2006, Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm, and Senior Vice President and Chief Financial Officer at COR Therapeutics. Ms. Brege currently serves as a Director of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD), Aratana Therapeutics, Inc. (NASDAQ: PETX), Dynavax Technologies Corporation (NASDAQ: DVAX) and Portola Pharmaceuticals, Inc. (NASDAQ: PTLA).

Ms. Brege earned her undergraduate degree from Ohio University and has an MBA from the University of Chicago.

Yvonne Greenstreet, MBChB, MBA,

Alnylam Pharmaceuticals, Inc

Yvonne Greenstreet has served as Executive Vice President and Chief Operating Officer of Alnylam Pharmaceuticals, a leading RNAi therapeutics company, since September 2016.

Prior to joining Alnylam, Dr.

Yvonne Greenstreet has served as Executive Vice President and Chief Operating Officer of Alnylam Pharmaceuticals, a leading RNAi therapeutics company, since September 2016.

Prior to joining Alnylam, Dr. Greenstreet was Senior Vice President and Head of Medicines Development at Pfizer.

Dr. Greenstreet was also at GlaxoSmithKline (GSK) for 18 years as Senior Vice President and Chief of Strategy for Research and Development. Dr. Greenstreet previously served in various positions of increasing responsibility at GSK, including Senior Vice President for Medicine Development, in which she led the creation of a new global unit which had responsibility for GSK's musculoskeletal, endocrine, gastrointestinal, ophthalmology and urological disease areas. Prior to this role, she was Chief Medical Officer for GSK Europe, with responsibility for development and medical affairs of GSK’s entire pipeline and product portfolio in the region.

Dr. Greenstreet currently serves on the Boards of Indivior PLC and Advanced Accelerator Applications S.A., as well as on the Scientific Advisory Board of the Bill and Melinda Gates Foundation.

Dr. Greenstreet trained as a physician and earned her medical degree from Leeds University in the UK and her MBA from INSEAD, France.

Mark Kronenfeld, MD

Maimonides Medical Center

Mark Kronenfeld has been the Vice Chairman of Anesthesiology at Maimonides Medical Center, a large tertiary care academic medical center in New York City, since March 2009, and has served as Medical Director of

Mark Kronenfeld has been the Vice Chairman of Anesthesiology at Maimonides Medical Center, a large tertiary care academic medical center in New York City, since March 2009, and has served as Medical Director of Perioperative Services for Maimonides Medical Center since January 2011. Dr. Kronenfeld is a managing partner of AABP, LP, a private medical practice, and a managing partner of Strategic Medical Management Partners and SORADS, a medical device incubator. In 2001, Dr. Kronenfeld founded Ridgemark Capital Management ("Ridgemark"), a healthcare-focused hedge fund that invested in public and private healthcare and biomedical companies. He served as the Managing Partner and Portfolio Manager of Ridgemark from April 2001 to December 2008. Dr. Kronenfeld has founded and/or managed various consulting and investment companies focused on healthcare and medical technologies and has served on and chaired multiple leadership committees for various hospitals and medical centers. Previously, Dr. Kronenfeld taught and practiced adult and pediatric cardiac anesthesia at NYU and was Chief of Cardiac Anesthesiology at Hackensack University Medical Center and President of GMS Anesthesia Associates, a private medical practice. Dr. Kronenfeld received his MD degree and completed his residency in Anesthesiology at the University of California, San Diego School of Medicine, and completed a fellowship in Cardiothoracic Anesthesiology at New York University Medical Center. While an Assistant Professor and Attending Cardiac Anesthesiologist at NYU, Dr. Kronenfeld received and completed a Kellogg-sponsored Fellowship in Health Care Management for Future Leaders in Health Care at NYU's Graduate School of Management.

John P. Longenecker, PhD

John P. Longenecker, PhD recently served as president and Chief Executive Officer of HemaQuest Pharmaceuticals, a private biotechnology company developing treatment for hemoglobinopathies, including sickle cell

John P. Longenecker, PhD recently served as president and Chief Executive Officer of HemaQuest Pharmaceuticals, a private biotechnology company developing treatment for hemoglobinopathies, including sickle cell disease and beta thalassemia, until May of 2014. Dr. Longenecker has 30 years’ experience in the biotech/pharmaceutical industry, including the startup and growth of multiple biotechnology companies. He has led efforts in all aspects of company development from startup venture capital funding, initial and secondary public offerings, corporate partnering, management of collaborations and mergers and acquisitions.

Prior to HemaQuest, Dr. Longenecker was president, Chief Executive Officer and Director of Favrille, Inc., a public biotechnology company developing personalized cancer vaccines for lymphoma. In 1992, he joined DepoTech (the precursor to Pacira) as Senior Vice President of Research, Development and Operations, and then served as President and Chief Operating Officer from February 1998 to March 1999. Under his leadership, DepoTech took its lead product, DepoCyt, from early pre-clinical research and development through to commercial launch.

Following SkyePharma PLC’s acquisition of DepoTech in 1999, Dr. Longenecker served as President for the U.S. Operations of SkyePharma Inc. and as a Member of the Executive Committee for SkyePharma PLC. From 1982 to 1992, he was at Scios (Cal Bio), a biotechnology company in the San Francisco Bay Area, where he served as Vice President and Director of Development. He was also a Director of a number of Cal Bio subsidiaries during this period, including Meta Bio and Karo Bio.

Dr. Longenecker obtained a BS from Purdue University in Lafayette, Indiana and a PhD in Biochemistry from The Australian National University in Canberra, Australia. He was a post-doctoral fellow at Stanford University from 1980 to 1982.

Gary W. Pace, PhD

Gary Pace is a seasoned biopharmaceutical executive with over 30 years of experience in the industry. He has co-founded a number of early stage life science companies, where he built products from the laboratory to

Gary Pace is a seasoned biopharmaceutical executive with over 30 years of experience in the industry. He has co-founded a number of early stage life science companies, where he built products from the laboratory to commercialization.

Dr. Pace was Director of QRxPharma Ltd (ASX: QRX) from 2001 through 2014. He is currently a Director of ResMed Inc. (NYSE: RMD) and Transition Therapeutics Inc (TSX: TTH). He is an elected Fellow of the Australian Academy of Technological Sciences and Engineering, as well as author and co-author of over 50 research papers, reviews and patents. In 2003, Dr. Pace was awarded a Centenary Medal by the Australian Government for service to Australian society in research and development. Dr. Pace holds a Bachelor of Science (Honors) from the University of New South Wales and a PhD from MIT, where he was a Fulbright Scholar.

Andreas Wicki, PhD

HBM Healthcare Investments AG

Andreas Wicki is Chief Executive Officer of HBM Healthcare Investments AG, Europe’s largest private equity focused investment company dedicated to life sciences. Prior to this role, from 1990-1998, he was co-owner

Andreas Wicki is Chief Executive Officer of HBM Healthcare Investments AG, Europe’s largest private equity focused investment company dedicated to life sciences. Prior to this role, from 1990-1998, he was co-owner and Chief Executive Officer of ANAWA Laboratorien AG and Clinserve AG, two life sciences CRO companies which he then sold to MDS Inc., a major life sciences services and clinical research organization. After the acquisition, from 1998-2001, he was Senior Vice President of the European Analytical Operations at MDS Inc., which allowed him to become more active in analyzing, selecting, and financing biotech and medtech companies.

Dr. Wicki holds an MSc and PhD in chemistry and biochemistry from the University of Bern, Switzerland. He currently serves on the Board of Directors of Buchler GmbH, HBM BioCapital Ltd., HBM Healthcare Investments (Cayman) Ltd., and Pacira Pharmaceuticals Inc.

Dennis L. Winger

Former CFO of Applera Corporation, Accuray Incorporated, Nektar Therapeutics

Dennis L. Winger has over 30 years of experience as a financial executive, with a focus on the life sciences industry. Most recently, Mr. Winger was Senior Vice President and Chief Financial Officer of Applera

Dennis L. Winger has over 30 years of experience as a financial executive, with a focus on the life sciences industry. Most recently, Mr. Winger was Senior Vice President and Chief Financial Officer of Applera Corporation, a life sciences company, from September 1997 until his retirement in December 2008. Previously, Mr. Winger served as Senior Vice President, Finance and Administration, and Chief Financial Officer of Chiron Corporation, a biotechnology company acquired by Novartis International in 2006. Mr. Winger currently serves as a director of Accuray Incorporated (NASDAQ: ARAY), a radiation oncology company, and Nektar Therapeutics (NASDAQ: NKTR), a clinical-stage biopharmaceutical company. He previously served on the boards of Vertex Pharmaceuticals Incorporated, from 2009 to 2012, Cephalon, Inc., from 2003 to 2011, and Cell Genesys, Inc., from 2004 to 2009. Mr. Winger also serves on the Board of Trustees of Siena College.

Mr. Winger holds a B.A. in History from Siena College and an M.B.A. from Columbia University Graduate School of Business.

Mark I. Froimson, MD

President of the American Association of Hip and Knee Surgeons(AAHKS), Former Executive Vice President and Chief Clinical Officer of Trinity Health

Mark I. Froimson, MD is currently serving as the President of the American Association of Hip and Knee Surgeons (AAHKS). Previously, he was the Executive Vice President and Chief Clinical Officer of Trinity Health, a

Mark I. Froimson, MD is currently serving as the President of the American Association of Hip and Knee Surgeons (AAHKS). Previously, he was the Executive Vice President and Chief Clinical Officer of Trinity Health, a major national non-profit Catholic healthcare system comprising 93 hospitals in 22 states. Prior to his executive leadership position at Trinity Health, Dr. Froimson was president and chief executive officer of Euclid Hospital, a Cleveland Clinic Hospital. Dr. Froimson served as a staff surgeon in the Department of Orthopedic Surgery at the Cleveland Clinic for over 16 years, during which time he held a variety of leadership positions including president of the professional staff, vice chair of the Orthopedic and Rheumatologic Institute, and member of the Board of Governors and Board of Trustees.

Dr. Froimson received a B.S. in philosophy from Princeton University, an M.D. from Tulane University School of Medicine and an MBA from the Weatherhead School of Business at Case Western Reserve University.